Retatrutide has been the most-hyped molecule in the pipeline for two years. That rests on a phase 2 obesity trial which took off nearly a quarter of body weight. Its first phase 3 result in type 2 diabetes reports 15.3%, and the gap between those two numbers is the thing most likely to be misread. This site covered the molecule’s first-in-human data when it appeared.
What TRANSCEND-T2D-1 measured
The trial randomized 537 adults whose type 2 diabetes was inadequately controlled by diet and exercise alone, at 48 sites across the USA, Mexico and India [1]. Average age was 48.8, average HbA1c 7.9%, average BMI 35.8, and average diabetes duration 2.5 years. These were people early in the disease, which is the easiest setting for a glucose drug.
HbA1c fell 1.69 points at 4 mg, 1.86 at 9 mg and 1.94 at 12 mg. The placebo arm fell 0.81 points over the same 40 weeks. That is large for a placebo, and it changes what the drug can be said to have done on its own.
Why the weight number looks smaller than you remember
| Phase 2 | TRANSCEND-T2D-1 | |
|---|---|---|
| Population | Obesity, no diabetes | Type 2 diabetes |
| Participants | 338 | 537 |
| Duration | 48 weeks | 40 weeks |
| Weight at 12 mg | −24.2% | −15.3% |
| Placebo arm | −2.1% | −2.6% |
The phase 2 trial enrolled adults with obesity and without diabetes. It reported 8.7%, 17.1%, 22.8% and 24.2% across 1, 4, 8 and 12 mg at 48 weeks, against 2.1% on placebo [2]. At 12 mg, 83% of participants lost at least 15% of their body weight, against 2% on placebo.
Setting 24.2% beside 15.3% therefore compares two different populations over two different durations. Weight loss runs consistently smaller in people with type 2 diabetes across this entire drug class, which is the established explanation rather than a sign that this drug underperformed. The molecule-by-molecule version of that pattern is in the pooled weight-loss averages.
Safety, as reported
Discontinuation for adverse events ran 2% to 5% on retatrutide and 0% on placebo, with gastrointestinal events most common and generally mild to moderate. No severe hypoglycemia was reported. Two deaths occurred during the study, both in the 4 mg group, and the paper describes both as unrelated to the study drug.
That is what the record says. It is not evidence of a dose-related hazard, since the two higher doses had none, and two events in a 537-person trial cannot establish a rate either way.
The phase 2 trial also recorded dose-dependent increases in heart rate that peaked at 24 weeks and declined afterwards. It found gastrointestinal events were partly mitigated by starting at 2 mg rather than 4 mg. That is the same escalation logic set out in what titration does to the nausea.
What this does not settle
Retatrutide is not approved and is not sold, a point worth repeating because the name circulates in gray-market listings — covered in what is not for sale. This trial also used placebo rather than an active comparator, so it establishes that a third receptor does not obviously break anything at 40 weeks in an easy population. Whether it beats the drugs already on pharmacy shelves is a different question, and nobody has run it.